Advertisement
Advertisement
U.S. markets close in 2 hours 6 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Agenus Inc. (AGEN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.5350+0.0050 (+0.33%)
As of 01:52PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close1.5300
Open1.5200
Bid1.5300 x 1100
Ask1.5400 x 4000
Day's Range1.4600 - 1.5400
52 Week Range1.4600 - 6.7900
Volume2,050,148
Avg. Volume4,626,573
Market Cap415.971M
Beta (5Y Monthly)1.24
PE Ratio (TTM)N/A
EPS (TTM)-0.0770
Earnings DateAug 08, 2022 - Aug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AGEN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Agenus Inc.
    Daily – Vickers Top Buyers & Sellers for 05/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    11 hours agoArgus Research
View more
  • Zacks

    Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates

    Agenus (AGEN) delivered earnings and revenue surprises of 34.48% and 49.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Agenus Corporate Update and First Quarter 2022 Financial Report

    Botensilimab data to be presented and Phase 2 trials to launch.AGEN1571 (ILT2) clinical trials to commence and data presented at AACR.AGEN2373 progressing in the clinic and Gilead milestone payment received. LEXINGTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today provided a corporate update and reported financial results for the fi

  • GlobeNewswire

    Agenus to Provide Corporate Update and First Quarter 2022 Financial Report

    Conference Call on Tuesday, May 10, 2022 at 8:30 a.m. ETLEXINGTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will release its first quarter 2022 financial results before the market opens on Tuesday, May 10, 2022. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the

Advertisement
Advertisement